COMP <GO>
PAHC vs UNH // EV/EBITDA & P/E VALUATION
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PAHC 4
— UNH 9
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 88.57% | -57.67 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 11.47% | -1.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.2x | 16.4x | +2.75 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 6.48% | -1.40 | UNH | /fcf-yield <GO> |
| Operating Margin | 8.50% | 4.82% | +3.68 | PAHC | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 3.14% | +0.56 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 6.46% | +20.94 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 2.28% | -1.05 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 3.12 | -0.25 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 59.2 | -2.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 17.1x | +10.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $368.83B | -$367.25B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | UNH REV | PAHC GROSS % | UNH GROSS % | PAHC FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $447.57B | 30.9% | 88.7% | $80.1M | $16.07B |
| FY 2024 | $1.02B | $400.28B | 30.8% | 88.3% | $87.6M | $20.70B |
| FY 2023 | $977.9M | $371.62B | — | 89.6% | $13.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
UNH // BETA 0.33